Urologic Oncology-seminars and Original Investigations最新文献

{"title":"Comparison of cardiovascular events in patients with metastatic hormone sensitive prostate cancer treated with LHRH agonists to LHRH antagonists in the US: A retrospective cohort study.","authors":"Renil S Titus, Eusebio Luna Velasquez, Vatsala Mundra, Carlos Riveros, Sanjana Ranganathan, David-Dan Nguyen, Amar Singh, Aamuktha Porika, Dharam Kaushik, Kershaw V Patel, Eleni Efstathiou, Christopher J D Wallis, Raj Satkunasivam","doi":"10.1016/j.urolonc.2026.09.012","DOIUrl":"https://doi.org/10.1016/j.urolonc.2026.09.012","url":null,"abstract":"<p><strong>Purpose: </strong>Androgen deprivation therapy (ADT) is standard treatment for metastatic hormone-sensitive prostate cancer (mHSCaP). Patients receive LHRH-agonists (LHRH-AG: leuprolide, goserelin or triptorelin) or LHRH-antagonists (LHRH-AN: degarelix or relugolix) with intensification with androgen receptor pathway inhibitors, with or without chemotherapy. Given ongoing concerns about cardiovascular risk, we used real-world data from TriNetX to compare the incidence of major adverse cardiovascular events (MACE) between patients receiving LHRH-AG vs. LHRH-AN.</p><p><strong>Materials and methods: </strong>We included adult patients with mHSCaP who received either an LHRH-AG or LHRH-AN. The composite primary outcome was MACE (defined as myocardial infarction (MI), stroke, or all-cause mortality). Secondary outcomes were MI, stroke, and all-cause mortality. Patients were 1:1 propensity-score matched (PSM). Kaplan-Meier analysis reporting hazard ratios (HR) and 95% confidence intervals (CI) for the outcomes was conducted. We conducted a subgroup analysis to assess the effect of intensification of therapy. Exploratory analyses were conducted to assess HR of outcomes and new-onset metabolic comorbidities (diabetes mellitus, insulin use, hypertension, and dyslipidemia) amongst patients without cardiovascular risk factors.</p><p><strong>Results: </strong>Before PSM, there were 27,051 in LHRH-AG and 3,339 in LHRH-AN cohorts. After PSM, 3,329 patients in each cohort were compared. Compared to LHRH-AN, LHRH-AG was associated with a decreased risk of MACE (hazard ratio [HR] = 0.86, 95% CI: 0.79-0.93), MI (HR = 0.80, 95% CI: 0.66-0.97), and any-cause mortality (HR = 0.85, 95% CI: 0.78-0.93). Treatment intensification did not modify the association between MACE outcomes and LHRH-AG vs. LHRH-AN.</p><p><strong>Conclusions: </strong>Using real-world data, LHRH-AG was associated with a decreased risk of experiencing MACE. Among those undergoing intensification of therapy, there was no difference in MACE risk associated with LHRH-AG vs. LHRH-AN.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149216791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence and predictors of prolonged opioid use following nephrectomy for renal cell carcinoma: A national claims-based study.","authors":"Baris Esen, Reza Lahiji, Dattatraya Patil, William Luke, Susan Mumford, Kelsey R Landrum, Lorenzo Storino Ramacciotti, Reza Nabavizadeh, Mohammad Hajiha, Valentina Grajales, Shreyas S Joshi, Vikram M Narayan, Kenneth Ogan, Viraj A Master","doi":"10.1016/j.urolonc.2026.09.014","DOIUrl":"https://doi.org/10.1016/j.urolonc.2026.09.014","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the incidence rates and risk factors of prolonged opioid use following nephrectomy for non-metastatic renal cell carcinoma (RCC) using a large national insurance database.</p><p><strong>Methods: </strong>Marketscan Commercial Claims and Encounters (MCCD) and Medicare Supplemental (MSD) databases were utilized to identify adult patients who underwent nephrectomy for RCC between 2009 and 2023. Patients with prior malignancy, metastatic disease during or within 12 months after surgery, inadequate insurance coverage, missing data, and opioid use within 90 days before surgery were excluded. The cumulative incidence of prolonged opioid use (≥2 prescriptions or ≥60 days of use between postoperative days 90-365) was determined. Multivariable logistic regression analyzed factors independently associated with prolonged opioid use.</p><p><strong>Results: </strong>10,098 patients from the MCCD and 2,980 from MSD were included. About 78% and 65% of patients received opioids during their early postoperative period in the MCCD and MSD databases, respectively. Prolonged opioid use occurred in 8.2% (MCCD) and 9.4% (MSD) of cases. Across both cohorts, higher comorbidity burden, geographic regions, certain insurance types, and greater early postoperative opioid use were independently associated with prolonged opioid use. In the MCCD cohort, female sex, non-metropolitan residence, and early postoperative emergency department visits were additionally associated with prolonged opioid use. Surgical type and operative approach were not significantly associated with the outcome in either cohort.</p><p><strong>Conclusion: </strong>Almost one in ten patients develops prolonged opioid use following nephrectomy for RCC. Early postoperative opioid exposure appeared strongly associated with prolonged opioid use, demonstrating a clear-dose response relationship. These findings support opioid-sparing strategies and the implementation of perioperative opioid stewardship programs to reduce prolonged opioid use in patients undergoing surgery for non-metastatic RCC.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149216844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Restricted mean survival time-based network meta-analysis of first-line therapies for metastatic clear cell renal cell carcinoma.","authors":"Joseph McGrath, Kevin Johnson, Nizar Hakam, Arjun Venkatesh, Yudai Ishiyama, Thomas Metzner, K C Balaji","doi":"10.1016/j.urolonc.2026.09.015","DOIUrl":"https://doi.org/10.1016/j.urolonc.2026.09.015","url":null,"abstract":"<p><p>To compare hazard ratio (HR)- and difference in restricted mean survival time (dRMST)-based network meta-analyses of first-line immune checkpoint inhibitor-based regimens for metastatic clear-cell renal cell carcinoma. We also introduce a RMST-based framework contextualizing survival benefit alongside toxicity, corticosteroid burden, and drug-acquisition cost. Five phase III trials comparing ICI-based combinations with sunitinib in mccRCC were included. Published trial-level HRs informed HR-based NMAs, while reconstructed individual patient data were used to estimate dRMST for OS at 40 to 64 months and PFS at 24 to 48 months. Frequentist common-effect models were used. Ranking concordance was assessed descriptively. Grade ≥3 treatment-related adverse events (TRAEs), high-dose corticosteroid use, and incremental drug-acquisition cost were evaluated relative to RMST-months gained. All regimens significantly improved dRMST vs. sunitinib for OS and PFS, except avelumab plus axitinib and nivolumab plus ipilimumab, respectively. For OS, nivolumab plus ipilimumab ranked first by HR, whereas nivolumab plus cabozantinib ranked first at every dRMST horizon. Lenvatinib plus pembrolizumab ranked first for PFS under both approaches. HR-dRMST concordance was greater in PFS across horizons, and concordance increased over time for both endpoints. dRMST provided clearer temporal separation and distinguished early vs. later accumulation of benefit. Nivolumab plus ipilimumab had the lowest grade ≥3 TRAE risk and the lowest drug-acquisition cost per RMST-month gained. RMST-based NMA yielded treatment rankings largely concordant to HR-based analysis while providing clearer distinction between regimens. These findings highlight the clinical value of RMST for integrating efficacy with toxicity, corticosteroid burden, and cost in treatment decision-making.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149216830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Project international Delphi consensus recommendations for perioperative management of inguinal lymphadenectomy in cancer patients.","authors":"Nahuel Paesano, Luis G Medina, Marcos Tobias-Machado, Jeremy Yuen-Chun Teoh, Amandeep Arora, Gagan Prakash, René Sotelo, Philippe E Spiess","doi":"10.1016/j.urolonc.2026.09.018","DOIUrl":"https://doi.org/10.1016/j.urolonc.2026.09.018","url":null,"abstract":"<p><strong>Objective: </strong>To establish international expert consensus on perioperative strategies for the prevention, management, and follow-up of complications related to inguinal lymph node dissection.</p><p><strong>Methods: </strong>This international modified Delphi consensus study was conducted between September 2025 and March 2026 using a 2-round electronic survey. A total of 101 experts from 25 countries participated, including urologists, surgical oncologists, plastic surgeons, and other specialists with experience in ILND for penile cancer, melanoma, and vulvar cancer. Eighty-six clinical statements addressing ILND-associated complications were evaluated across 6 domains: preoperative nutritional optimization, anemia management, lymphatic complications, infectious and cutaneous complications, vascular and musculoskeletal complications, and functional rehabilitation. Agreement was assessed using a 5-point Likert scale, with consensus defined a priori as at least 70% of participants selecting \"somewhat agree\" or \"strongly agree.\"</p><p><strong>Results: </strong>Consensus was achieved for 51 of 86 statements. Agreed recommendations supported standardized approaches to preoperative nutritional assessment and anemia correction, prevention and management of lymphatic complications, drain placement and management, discharge criteria, antibiotic prophylaxis, wound complication management, thromboprophylaxis, multimodal analgesia, and early functional rehabilitation. No consensus was reached regarding routine use of immunonutrition, optimal duration of antibiotic therapy, topical treatments, muscle relaxants, or hyperbaric oxygen therapy.</p><p><strong>Conclusions: </strong>This international Delphi process generated consensus-based, multidisciplinary recommendations to guide perioperative ILND management. These statements may provide a structured framework to support greater standardization of perioperative care pathways across malignancies requiring ILND, reduce morbidity, and inform quality-improvement initiatives. Prospective validation is required to evaluate their clinical impact and refine areas of ongoing uncertainty.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149208165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prospectively collected functional vs. self-reported frailty measures and postoperative outcomes after radical cystectomy in older adults with bladder cancer.","authors":"Jordan Sheldon, Sarah Holt, Elena Brewer, John L Gore, Jose M Garcia, May Reed, Itay Bentov, Donna Berry, Viraj A Master, Matthew P Kirschenbaum, Marielle Yano, Grace Jun, Casey Li, Sarah P Psutka","doi":"10.1016/j.urolonc.2026.09.010","DOIUrl":"10.1016/j.urolonc.2026.09.010","url":null,"abstract":"<p><strong>Introduction and objectives: </strong>The optimal tools to measure frailty in patients with bladder cancer are poorly defined. Our objective was to compare baseline physical function with self-reported frailty assessments, and to evaluate associations between functional vs. self-reported frailty assessments and postoperative outcomes.</p><p><strong>Methods: </strong>Adults ≥65 years old with bladder cancer anticipating radical cystectomy (RC) were preoperatively assessed with the Short Physical Performance and Battery Assessment (SPPB): a physical assessment evaluating balance, gait speed, and lower extremity strength; and the Care and Aging Resilience Evaluation-Geriatric Assessment: a self-reported form which generates a validated frailty index (CARE-FI). Associations between the two frailty measures, postoperative length of stay (LOS), and 90-day grade ≥3 Clavien Dindo complications were assessed.</p><p><strong>Results: </strong>About 53 participants were analyzed. Overall, 3/53 were frail per the CARE-FI, while 1/53 demonstrated poor performance per SPPB criteria. CARE-FI and SPPB frailty categories were strongly associated on an ordinal scale (Kendall's τ-b = 0.88, P = 0.02), agreement between categorical classifications was limited (weighted κ = 0.02). Patients classified as frail or pre-frail by CARE-FI were more likely to experience extended length of stay (≥7 days; P = 0.008, chi-square) and had a longer continuous LOS (P = 0.0013, Wilcoxon rank-sum) and were also more likely to experience a grade ≥3 complication (P = 0.04, chi-square). The SPPB was not significantly associated with either variable per chi squared analysis (P > 0.05 for both).</p><p><strong>Conclusions: </strong>Functional and self-reported frailty assessments provide different information characterizing individual vulnerability profiles; however, only the CARE-FI was statistically associated with increased LOS and postoperative complications following RC.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13674010/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149196859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing patient-reported urinary and sexual bother and function after robotic-assisted radical prostatectomy.","authors":"Behnam Nabavizadeh, Judy Zhong, Bashir Al Hussein Al Awamlh, Jim C Hu","doi":"10.1016/j.urolonc.2026.09.013","DOIUrl":"https://doi.org/10.1016/j.urolonc.2026.09.013","url":null,"abstract":"<p><strong>Purpose: </strong>Functional recovery after robot-assisted radical prostatectomy (RARP) does not always align with patient-perceived bother. To evaluate urinary/sexual bother-function relationships and time to acceptable bother using the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP).</p><p><strong>Materials and methods: </strong>We performed a retrospective cohort study of consecutive men undergoing RARP (April 2015-August 2025) who completed preoperative and ≥1 postoperative EPIC-CP assessment. The primary outcome was the strength of association between urinary function and urinary bother and between sexual function and sexual bother at 3, 12, and 24-months, quantified using Spearman correlation coefficients. Secondary outcomes included factors associated with urinary and sexual bother (multivariable linear regression) and time to acceptable bother (bother score≤1) estimated using Kaplan-Meier methods.</p><p><strong>Results: </strong>The cohort included 552 men (median age 65 [interquartile range 59-70] years). Urinary leakage frequency demonstrated moderate-to-high correlations with urinary bother at 3, 12, and 24-months (ρ = 0.71, 0.60, 0.77; all P < 0.001), and pad use demonstrated weaker correlation (ρ = 0.67, 0.57, 0.45; all P < 0.001). Erection quality demonstrated low-to-moderate correlations with sexual bother (ρ = 0.44, 0.46, 0.50; all P < 0.001). Pelvic fascia-sparing and increasing surgeon experience were associated with less early urinary bother, whereas sexual bother was associated with baseline sexual symptoms score and patient factors (age and BMI). Median time to acceptable urinary bother was 3.9-months, compared to 23.7-months for acceptable sexual bother (P < 0.001).</p><p><strong>Conclusions: </strong>Urinary bother correlates with urinary leakage frequency more than pad use, while sexual bother is less strongly related to erection quality and improves more slowly. Incorporating bother alongside function better reflects patient-centered recovery after RARP.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149184799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transitioning from template-based groin dissection to dynamic sentinel node biopsy in penile cancer: Prospective validation of a standardization step.","authors":"Gagan Prakash, Sarah Shaikh, Amandeep Arora, Mahendra Pal, Ankit Misra, Ajit Gujela, Ganesh Bakshi, Venkatesh Rangarajan, Archi Agrawal, Santosh Menon","doi":"10.1016/j.urolonc.2026.09.009","DOIUrl":"https://doi.org/10.1016/j.urolonc.2026.09.009","url":null,"abstract":"<p><strong>Purpose: </strong>Dynamic sentinel lymph node biopsy (DSNB) offers accurate inguinal staging in clinically node-negative (cN0) penile cancer (PeCa), but implementation requires multidisciplinary expertise and standardization. We evaluated the feasibility and diagnostic accuracy of a standardized dual-tracer DSNB protocol during transition from modified/superficial inguinal lymph node dissection (MILD/SILD).</p><p><strong>Methods: </strong>In this prospective, non-randomized phase II study, 20 patients with intermediate- or high-risk cN0 PeCa underwent DSNB followed by MILD and SILD in both groins. DSNB used 99mTc-nanocolloid and indocyanine green (ICG). Sentinel nodes were identified using lymphoscintigraphy/SPECT-CT, gamma-probe and near-infrared fluorescence, and assessed by frozen section. Final SILD pathology served as the reference standard for calculating the false-negative rate (FNR).</p><p><strong>Results: </strong>Forty groins were evaluated. DSNB successfully identified sentinel nodes in 37/40 (92.5%) groins; ICG identified nodes in 36 (90%) compared with 28 (70%) for 99mTc. Five groins contained metastatic sentinel nodes, all detected by DSNB, yielding 100% sensitivity and 0% FNR. In 4/37 (10.8%) successful procedures, sentinel nodes lay outside the MILD template. Median sentinel node yield was 4 versus 12 nodes with SILD. Median drain duration and hospital stay were 21 and 3 days, respectively. Eleven patients (55%) had no complications; grade 2 and 3a complications occurred in 20% and 25%, respectively. After median follow-up of 34 months, no inguinal nodal recurrences occurred.</p><p><strong>Conclusion: </strong>A standardized dual-tracer DSNB protocol was feasible and demonstrated high diagnostic accuracy during phased implementation at a tertiary cancer centre. Initial validation alongside template dissection may facilitate safe adoption, particularly in settings without centralized PeCa services.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149184752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Translational research models for variant subtype bladder cancers: A comprehensive review of the current landscape.","authors":"Gabriella U Nanjo, Zirui Fu, Shayan Smani, Soum D Lokeshwar, Joshua Warrick, Deepika Kumar, William Kim, Curtis J Perry, Wei Shen Tan, Ping Mu, Darryl T Martin, Fady Ghali","doi":"10.1016/j.urolonc.2026.09.008","DOIUrl":"10.1016/j.urolonc.2026.09.008","url":null,"abstract":"<p><p>Bladder cancer remains a leading cause of cancer-related mortality in the United States, with most cases classified as conventional urothelial carcinoma. However, a substantial subset of patients presents with aggressive variant histologies, including sarcomatoid, plasmacytoid, and micropapillary subtypes. These variants are associated with early dissemination, treatment resistance, and limited evidence to guide subtype specific management. Despite their clinical relevance, progress in mechanistic understanding and therapeutic development has been hindered due to rarity, underrepresentation in clinical trials, and a research focus on conventional disease. A key impediment is the lack of translational model systems that maintain variant defining morphology, lineage programs, and tumor microenvironmental interactions. Recent advances in translational modeling technologies now provide new opportunities to interrogate the unique biology of variant subtype bladder cancers. In this review, we highlight key preclinical models commonly used in bladder cancer research, including patient-derived xenografts, humanized models, syngeneic systems, genetically engineered mouse models, organoids, and ex vivo explants, and highlight emerging applications in variant histologies. We also discuss innovative and integrative platforms, including hybrid experimental systems and computational approaches, that are beginning to overcome barriers imposed by tumor rarity and heterogeneity. Collectively, these evolving model systems will enable more faithful representation of variant subtype biology, tumor-microenvironment interactions, and therapeutic vulnerabilities, and provide a framework for developing subtype-specific, precision treatment strategies.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149184721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to \"Calendar-time bias in a TriNetX study of GLP-1 receptor agonists, SGLT2 inhibitors and bladder cancer survival\".","authors":"Jakob Kohler, Severin Rodler","doi":"10.1016/j.urolonc.2026.09.016","DOIUrl":"https://doi.org/10.1016/j.urolonc.2026.09.016","url":null,"abstract":"","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149184741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction notice to \"Association of genetic polymorphism of glutathione S-transferase (GSTM1, GSTT1, GSTP1) with bladder cancer susceptibility\" [Urologic Oncology: Seminars and Original Investigations 31 (2013) 1193-1203].","authors":"Mohammad Reza Safarinejad, Saba Safarinejad, Nayyer Shafiei, Shiva Safarinejad","doi":"10.1016/j.urolonc.2026.08.008","DOIUrl":"10.1016/j.urolonc.2026.08.008","url":null,"abstract":"","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149167366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}